The problem with this is that the world becomes increasingly more like an economy. It makes more sense to spend $10 trillion on infrastructure than to build something more durable. In addition, if governments were willing to pay for this, I’d bet on $5 trillion per year.
This is a problem with many policies, whether in the US or the UK. I was in Washington last week, and they have to do something about climate change. In London, the same issues are more complicated, but not as much more complicated than in Washington, because it’s a political issue. The UK is going after gas with its proposed carbon capture and storage scheme, but not coal. How does Britain decide which power source to use? That may be the trickiest part of the puzzle: we’re dealing with an ecosystem that can’t handle too many different power sources. I’m hopeful that there will be a consensus in Europe to do something. I also hope that it’s possible to get a global emissions reduction deal from the EU. It would be the best thing for the planet, and it would be an improvement over any one country’s policy. But it’s not going to happen by itself.
The National Institutes of Health wants to expand the availability of its new breast cancer drug Cetuximab. The drug doesn’t have many other uses and it was only approved in 2000. But researchers who have worked with Cetuximab say it can help women with a rare form of breast cancer who don’t respond to other treatments.
Currently, Cetuximab is only available to some women with a form of the cancer known as advanced breast cancer. In order to qualify for the drug, they have to have to have a high levels of a protein called interleukin-6, but not an aggressive form of the cancer. These women can’t currently take other therapies, such as radiation or chemotherapy. There is one group of women who could benefit from Cetuximab, however: pregnant women who may be at high risk for miscarriage.
“They can develop a life-threatening infection through a pregnancy and then when they deliver a baby it could potentially spread that infection to the foetus,” said Dr. Bruce Blumberg, chief of breast cancer at Northwestern Memorial Hospital. “We’ve been looking at these women who would be at high risk for this disease and we have found that these women can have much better survival outcomes if they are already on Cetuximab than if they don’t get